Related Experiment Videos
Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis
R Patel1, M S Rouse, K E Piper
1Division of Infectious Diseases and Infectious Diseases Research Laboratory, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. patel.robin@mayo.edu
Antimicrobial Agents and Chemotherapy
|February 13, 2001
Summary
Linezolid demonstrates superior activity against vancomycin-resistant Enterococcus faecium endocarditis in rats. This study found linezolid significantly reduced bacterial load compared to vancomycin and untreated controls.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Vancomycin-resistant Enterococcus faecium (VRE) poses a significant threat in healthcare settings.
- Endocarditis caused by VRE is difficult to treat with conventional antibiotics.
- Novel therapeutic strategies are crucial for combating VRE infections.
Purpose of the Study:
- To compare the efficacy of linezolid and vancomycin in a rat model of VRE endocarditis.
- To evaluate the impact of linezolid treatment on bacterial load in vegetations.
- To determine if linezolid offers an advantage over vancomycin for VRE endocarditis.
Main Methods:
- A rat model of experimental endocarditis was established using vanA VRE.
- Animals were treated with linezolid (25 mg/kg, IP every 8 h) or vancomycin (25 mg/kg, IP every 8 h).
- Bacterial burden (log10 CFU/g vegetation) was quantified after 3 days of treatment.
Main Results:
- Untreated controls had a median bacterial load of 10.1 log10 CFU/g.
- Vancomycin treatment resulted in a median load of 10.2 log10 CFU/g.
- Linezolid treatment significantly reduced the bacterial load to 7.9 log10 CFU/g (P < 0.05).
Conclusions:
- Linezolid exhibits significantly greater antimicrobial activity than vancomycin against VRE endocarditis in this preclinical model.
- Linezolid represents a promising therapeutic option for treating VRE endocarditis.
- Further clinical investigation is warranted to confirm these findings in human patients.